JPS624362B2 - - Google Patents
Info
- Publication number
- JPS624362B2 JPS624362B2 JP58221708A JP22170883A JPS624362B2 JP S624362 B2 JPS624362 B2 JP S624362B2 JP 58221708 A JP58221708 A JP 58221708A JP 22170883 A JP22170883 A JP 22170883A JP S624362 B2 JPS624362 B2 JP S624362B2
- Authority
- JP
- Japan
- Prior art keywords
- cream
- moisturizing
- skin
- cosmetics
- cps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000006210 lotion Substances 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 9
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 9
- 239000004909 Moisturizer Substances 0.000 claims description 9
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 9
- 230000001333 moisturizer Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000344 soap Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008294 cold cream Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 description 36
- 210000003491 skin Anatomy 0.000 description 19
- 239000002674 ointment Substances 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002075 main ingredient Substances 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- -1 Polyoxyethylene cetyl ether Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000001557 animal structure Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Description
本発明は、皮膚保湿剤として、動物の臓器より
抽出したコンドロイチン硫酸の多硫酸エステルを
有効成分とする皮膚用保湿剤殊に保湿性皮膚用化
粧品に関するものである。
正常な人の皮膚では、適度の皮脂(Sebum)
が分泌されており、その中に含まれる各種のトリ
グリセライド、ロウ、コレステロール、スクワレ
ン及びパラフイン系炭化水素その他の諸成分が保
湿成分として皮膚の乾きすぎを防ぐと共に、その
しなやかさを保つ保用をしている。ところが老化
した皮膚、荒れ性のヒトの皮膚又は洗剤を頻繁に
使用したヒトの皮膚では、皮脂が不足しているた
め、皮膚が干からびたり、荒れた皮膚となる。
以上のように、自然の保湿作用が不充分である
場合、保湿性を持つ物質を人為的に皮膚に補給し
て皮膚の乾きすぎを防ぐことは古くから行なわれ
ており、例えば化粧品に対してはグリセリン、プ
ロピレングリコール、ソルビトール又はジエチレ
ングリコール・モノエチルエーテル(又はモノメ
チルエーテル)などの保湿剤が普遍的に配合され
ていることは周知である。
ところで、ヒトの皮膚に適用される保湿剤は、
目的上、空気中の湿度が低いときは水分を蒸発さ
せず保持し、一方湿度が高いときでも一定限度以
上には水分を吸収しない特性を持つのが望まし
い。換言すれば、理想的な保湿剤は、Natural
Moisturizing Factor(NMF:皮膚表面にある生
理的保湿成分として角質化の代謝産物あるいは汗
由来の吸湿性の顕著な物質)の代表とされている
ピロリドンカルボン酸ナトリウム(Sodium
pyrrolidone carboxylate(PCA−Na))と同等又
はそれ以上の性能を備えるべきである。しかる
に、上記の既知保湿剤は、過度の吸湿性のため、
ベタつき易いという欠点がある。
そこで近年に至り、上のPCAに比し保湿効果
がより優れたものとしてムコ多糖類が注目される
ようになり、これに属するコンドロイチン硫酸又
はヒアルロン酸を含む化粧品が種々検討され、一
部これらを含む化粧品が市販されている。
本発明者は、動物の臓器より抽出したコンドロ
イチン硫酸の多硫酸エステル(以下CPSと略す)
の保湿作用について鋭意研究した結果、本エステ
ル類が保湿剤として上記コンドロイチン硫酸やヒ
アルロン酸に比べて遥に優れているとの知見が得
られた。このCPSは、ヘパリノイド物質として、
抗トロンビン作用、抗血液凝固作用及び末梢血液
の循環促進作用を有することが知られているが、
その保湿作用、殊に皮膚化粧料における保湿作用
についてはこれまで未知であつたものである。因
に本発明者らは、保湿効果を客観的に測定する手
段として皮表角層の水含量を田上ら(Tagami、
H.、Ohi、M.、Iwatsuki、K.、Kanamaru、Y.、
Yamada M and ichijo、B.:Evaluation of the
skin surface hydration in vivo by electrical
measurement、J.Invest.Dermatol.、75、:500
−507、1980)によつて開発された高周波伝導に
よる測定方法(インピーダンスメーター法)を採
用したが、この測定法は、官能的観察結果とよく
符合していることが分つた。
[実験方法]
インピーダンスメーターを用いて、(1a)0.3%
CPS含有軟膏、(1b)0.1%CPS含有軟膏及び
(1c)基剤のそれぞれの保湿効果の比較、並びに
(2a)0.3%CPS含有軟膏と保湿効果を謳つている
市販品A(主成分:尿素)、B(主成分:可溶性
コラーゲン)、C(主成分:ヒアルロン酸)及び
D(主成分:天然保湿成分類似物)の保湿効果に
ついて以下の条件で検討した。
被検者:男5名、女5名
塗布方法:部位−左右の前腕内側、
面積−約13cm2、
量−50μ
以上実験(1a)、(1b)及び(1c)の結果を表
1及び第1図に、実験(2a)、(2−A)、(2−
B)、(2−C)及び(2−D)の結果を表2及び
第2図に示す。
The present invention relates to a skin moisturizer, particularly a moisturizing skin cosmetic, which contains as an active ingredient a polysulfate ester of chondroitin sulfate extracted from animal organs. In normal human skin, moderate sebum (Sebum)
The various triglycerides, waxes, cholesterol, squalene, paraffinic hydrocarbons, and other components contained in these act as moisturizing ingredients that prevent the skin from becoming too dry and maintain its suppleness. ing. However, in aged skin, rough skin, or skin that has frequently used detergents, the skin becomes dry and rough due to a lack of sebum. As mentioned above, when the natural moisturizing effect is insufficient, artificially replenishing the skin with moisturizing substances to prevent the skin from drying out has been practiced for a long time.For example, it has been used in cosmetics. It is well known that moisturizing agents such as glycerin, propylene glycol, sorbitol, or diethylene glycol monoethyl ether (or monomethyl ether) are commonly included in the formulation. By the way, moisturizers applied to human skin are
For this purpose, it is desirable to have the property of retaining moisture without evaporating when the humidity in the air is low, while not absorbing moisture above a certain limit even when the humidity is high. In other words, the ideal moisturizer is Natural
Sodium pyrrolidone carboxylate is a representative of Moisturizing Factor (NMF: a metabolic product of keratinization or a highly hygroscopic substance derived from sweat as a physiological moisturizing component on the skin surface).
It should have performance equivalent to or better than pyrrolidone carboxylate (PCA-Na)). However, the above-mentioned known moisturizers have excessive hygroscopicity,
It has the disadvantage of being easily sticky. In recent years, mucopolysaccharides have attracted attention as they have better moisturizing effects than the above-mentioned PCA, and various cosmetics containing chondroitin sulfate or hyaluronic acid, which belong to these mucopolysaccharides, have been investigated, and some of them have been Cosmetics containing it are commercially available. The present inventor has developed a polysulfate ester of chondroitin sulfate (hereinafter abbreviated as CPS) extracted from animal organs.
As a result of intensive research on the moisturizing effect of esters, it was found that these esters are far superior to the above-mentioned chondroitin sulfate and hyaluronic acid as humectants. This CPS is a heparinoid substance,
It is known to have antithrombin effects, anticoagulant effects, and peripheral blood circulation promoting effects.
Its moisturizing effect, especially its moisturizing effect in skin cosmetics, was unknown until now. Incidentally, the present inventors measured the water content of the stratum corneum of the skin as a means of objectively measuring the moisturizing effect.
H., Ohi, M., Iwatsuki, K., Kanamaru, Y.,
Yamada M and Ichijo, B.: Evaluation of the
skin surface hydration in vivo by electrical
measurement, J. Invest. Dermatol., 75, : 500
We adopted a high-frequency conduction measurement method (impedance meter method) developed by J.D.-507, 1980), and found that this measurement method corresponded well with the sensory observation results. [Experiment method] Using an impedance meter, (1a) 0.3%
Comparison of the moisturizing effects of CPS-containing ointment, (1b) 0.1% CPS-containing ointment, and (1c) base, and (2a) 0.3% CPS-containing ointment and commercial product A (main ingredient: urea) that claims a moisturizing effect. ), B (main ingredient: soluble collagen), C (main ingredient: hyaluronic acid), and D (main ingredient: natural moisturizing ingredient analogue) were examined under the following conditions. Subjects: 5 men, 5 women Application method: Site: Inside of left and right forearms, Area: approx. 13 cm 2 , Amount: 50μ or more The results of experiments (1a), (1b), and (1c) are shown in Tables 1 and 1. Figure 1 shows experiments (2a), (2-A), (2-
The results of B), (2-C) and (2-D) are shown in Table 2 and FIG.
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】
表1及び第1図が示す如く、0.3%のCPSを含
有する軟膏では、塗布後30分より顕著な保湿効果
がみられ、その効果は、適用後6時間経過後も持
続した。0.1%のCPSを含有する軟膏では、4時
間経過後より基剤より高い保湿効果がみられ、6
時間経過後も塗布前より高い値を示し、高い保湿
効果を有することが認められた。
表2及び第2図に示した0.3%CPS含有軟膏と
保湿効果を謳つている一般市販品(医薬品及び医
薬部外品)との保湿効果の比較において、尿素を
主成分とする医薬品Aは、塗布直後比較的高に保
湿効果を示したが、経時的に保湿能が低下し、塗
布6時間後には、ほぼ塗布前の値まで低下した。
また、可溶性コラーゲンを主成分とする医薬部外
品Bは、塗布直後以外、特に大きな保湿効果は示
さなかつた。さらにヒアルロン酸を有効成分とし
て含むC(医薬部外品、軟膏)は、予想に反し、
塗布30分後に早くも塗布前の値まで低下した。そ
してA、B及びCのいずれも6時間後には殆ど保
湿作用が消滅している。最後に、天然保湿成分類
似物を含む医薬部外品Dは、塗布後6時間経過後
も比較的高い値を示したものの、その保湿効果
は、本発明品(CPS0.3%含有)に比し劣つてい
た。これら実験結果から、本発明に係るCPS含有
皮膚用保湿剤は、既存市販品に比べてより優れた
保湿効果を有することは明白である。なお、発明
者は前記各実験に加え、化粧料用保湿剤として従
前から慣用されているコンドロイチン硫酸
(ChS)入り軟膏を対照として前各表と同様の生
体テストを行なつた。但し、この場合の被検者は
男子5名である。結果を下表−3及び第3図とし
て示す。表(図)示の如く、発明に係るCPS入り
軟膏は、適用30分以後、対照のChS入り軟膏に比
べて歴然たる保湿能を示し、6時間経過後もない
高い保湿水準を示している事実が窺われる。[Table] As shown in Table 1 and Figure 1, the ointment containing 0.3% CPS had a noticeable moisturizing effect from 30 minutes after application, and the effect continued even 6 hours after application. The ointment containing 0.1% CPS showed a higher moisturizing effect than the base after 4 hours;
Even after the passage of time, the value remained higher than before application, indicating that it had a high moisturizing effect. In comparing the moisturizing effects of ointments containing 0.3% CPS shown in Table 2 and Figure 2 with general commercial products (drugs and quasi-drugs) that claim to have a moisturizing effect, Pharmaceutical A, which has urea as its main ingredient, Immediately after application, it showed a relatively high moisturizing effect, but the moisturizing ability decreased over time, and 6 hours after application, it decreased to almost the value before application.
Furthermore, quasi-drug B containing soluble collagen as a main component did not exhibit particularly large moisturizing effects except immediately after application. Furthermore, C (quasi-drug, ointment) containing hyaluronic acid as an active ingredient, contrary to expectations,
As early as 30 minutes after application, the value decreased to the value before application. The moisturizing effect of all of A, B and C almost disappeared after 6 hours. Finally, although quasi-drug D containing analogues of natural moisturizing ingredients showed a relatively high value even 6 hours after application, its moisturizing effect was lower than that of the product of the present invention (containing 0.3% CPS). It was inferior. From these experimental results, it is clear that the CPS-containing skin moisturizer according to the present invention has a better moisturizing effect than existing commercially available products. In addition to the above-mentioned experiments, the inventors also conducted in vivo tests similar to those listed in the preceding tables using an ointment containing chondroitin sulfate (ChS), which has been conventionally used as a moisturizing agent for cosmetics, as a control. However, the subjects in this case are 5 males. The results are shown in Table 3 below and Figure 3. As shown in the table (figure), the CPS-containing ointment according to the invention shows a clear moisturizing ability compared to the control ChS-containing ointment after 30 minutes of application, and shows the highest level of moisturizing even after 6 hours. is seen.
【表】
本発明は以上の知見に基ずくものであつて、そ
の要旨は、CPSを皮膚用保湿剤として利用する点
に在る。この目的を達成するため、本発明に係る
皮膚用保湿剤は、好ましくは化粧石鹸、透明石
鹸、又はクレンジングクリーム等の洗浄料、コー
ルドクリーム、ハンドクリーム、バニシングクリ
ーム、フアンデーシヨンクリーム、ホルモンクリ
ーム(エモリエントクリームにエストロゲンを含
有させたもの)などのクリーム類、植物汁液性化
粧水、アルカリ性化粧水、アストリンジエントロ
ーシヨン、ハンドローシヨン、乳液、フアンデー
シヨンローシヨン、クレンジングローシヨンなど
の化粧水類、粉オシロイ、水オシロイ、練オシロ
イなどのオシロイ類及び口紅等の剤形としてヒト
の皮膚に適用される。これらの製剤の原料として
は、動植物性油脂類、動植物性ロウ類、スクワラ
ン、ラノリン、ミクロクリスタリンロウ、セレシ
ンロウ、パラフインロウ、ワセリン、流動パラフ
イン、高級脂肪酸類、高級脂肪属アルコール類、
高級脂肪属エステル類、各種界面活性剤、天然又
は半合成多糖類及びその誘導体類、グリセリン、
プロピレングリコール、ソルビトール、種々の殺
菌剤又は保存剤、抗酸化剤、種々の着香料、充填
剤(賦形材)及び着色料などの公知の香粧料原料
が使用される。CPSは、組成物中通常0.1〜1.0
%、好ましくは、0.1〜0.3%の範囲内で存在する
のが望ましい。
以下、実施例により発明実施の態様を説明する
が、例示は単に説明用のものであつて、発明範囲
の限定を意図するものではない。
実施例 1
(ハンドクリーム)
以下の各成分を70〜75℃に予熱後、ホモミキサ
ーを用いて撹拌、乳化させた後、冷却し、さらに
必要に応じホモジナイザーを通して均質化させ、
製品とする。
処方例 1
白色ワセリン 10.0g
セタノール 10.0g
ラノリンアルコール 5.0g
コレステロール 1.0g
グリセリルモノステアレート 1.0g
ポリオキシエチレンセチルエーテル 1.0g
CPS 0.3g
水 適量
計 100.0g
処方例 2
流動パラフイン 30.0g
セタノール 3.0g
パラフインワツクス 5.0g
プロプレングリコール 5.0g
グリセリルモノステアレート 1.8g
ポリオキシエチレン モノステアレート 2.0g
CPS 0.1g
水 適量
計 100.0g
処方例 3
白色ワセリン 25.0g
ステアリルアルコール 22.0g
プロピレングリコール 12.0g
ラウリル硫酸ナトリウム 1.5g
パラオキシ安息香酸エチル 0.025g
パラオキシ安息香酸プロピル 0.015g
CPS 0.3g
水 適量
計 100.0g
実施例 2
(ハンドローシヨン)
以下の諸成分をホモミキサーを用いて撹拌、混
合して製品とする。
処方例 4
ソルビトール 4.0g
クエン酸 0.9g
エタノール 10.0ml
メチルパラベン 0.1g
CPS 0.3g
水 適量
計 100.0g
処方例 5
(同上)
トリエタノールアミン 0.2g
1・3−ブチレングリコール 7.0g
エタノール 20.0ml
メチルパラベン 0.1g
CPS 0.3g
水 適量
計 100.0g[Table] The present invention is based on the above findings, and its gist lies in the use of CPS as a skin moisturizer. To achieve this objective, the skin moisturizer according to the present invention preferably includes a cleansing agent such as a cosmetic soap, a transparent soap, or a cleansing cream, a cold cream, a hand cream, a vanishing cream, a foundation cream, a hormone cream ( Creams such as emollient cream containing estrogen), lotions such as plant juice lotions, alkaline lotions, astringent lotions, hand lotions, milky lotions, foundation lotions, and cleansing lotions. It is applied to human skin in the form of cosmetics such as powder, water, and kneaded products, as well as lipstick. Raw materials for these preparations include animal and vegetable oils and fats, animal and vegetable waxes, squalane, lanolin, microcrystalline wax, ceresin wax, paraffin wax, petrolatum, liquid paraffin, higher fatty acids, higher fatty alcohols,
Higher fatty esters, various surfactants, natural or semi-synthetic polysaccharides and their derivatives, glycerin,
Known cosmetic raw materials such as propylene glycol, sorbitol, various disinfectants or preservatives, antioxidants, various flavoring agents, fillers (excipients), and coloring agents are used. CPS is usually 0.1-1.0 in the composition
%, preferably within the range of 0.1 to 0.3%. Hereinafter, embodiments of the invention will be described with reference to Examples, but the examples are merely for illustration purposes and are not intended to limit the scope of the invention. Example 1 (Hand Cream) After preheating the following ingredients to 70 to 75°C, stir and emulsify using a homomixer, cool, and if necessary homogenize through a homogenizer.
Product. Prescription example 1 White petrolatum 10.0g Setanol 10.0g Lanolin alcohol 5.0g Cholesterol 1.0g Glyceryl monostearate 1.0g Polyoxyethylene cetyl ether 1.0g CPS 0.3g Water Dosage meter 100.0g Prescription example 2 Liquid paraffin 30.0g Setanol 3.0g Paraffin wax Tsukusu 5.0g Proprene glycol 5.0g Glyceryl monostearate 1.8g Polyoxyethylene monostearate 2.0g CPS 0.1g Water Dosage meter 100.0g Prescription example 3 White petrolatum 25.0g Stearyl alcohol 22.0g Propylene glycol 12.0g Sodium lauryl sulfate 1.5g Ethyl paraoxybenzoate 0.025g Propyl paraoxybenzoate 0.015g CPS 0.3g Water Dosage meter 100.0g Example 2 (Hand lotion) The following ingredients are stirred and mixed using a homomixer to prepare a product. Prescription example 4 Sorbitol 4.0g Citric acid 0.9g Ethanol 10.0ml Methylparaben 0.1g CPS 0.3g Water Dosage meter 100.0g Prescription example 5 (Same as above) Triethanolamine 0.2g 1,3-butylene glycol 7.0g Ethanol 20.0ml Methylparaben 0.1g CPS 0.3g water dosage meter 100.0g
第1図は、本発明に係るCPS含有軟膏と対照
CPS無含有軟膏の保湿効果を比較したグラフ、第
2図は、本発明に係るCPS含有軟膏と市販保湿性
軟膏の保湿効果を比較したグラフ、第3図は、本
発明に係るCPS含有軟膏と公知のコンドロイチン
硫酸入り軟膏との保湿効果を比較したグラフであ
る。
Figure 1 shows a CPS-containing ointment according to the present invention and a control
A graph comparing the moisturizing effect of CPS-free ointments, Figure 2 is a graph comparing the moisturizing effects of the CPS-containing ointment according to the present invention and a commercially available moisturizing ointment, and Figure 3 is a graph comparing the moisturizing effects of the CPS-containing ointment according to the present invention and the commercially available moisturizing ointment. It is a graph comparing the moisturizing effect with a known ointment containing chondroitin sulfate.
Claims (1)
ルを有効成分とする皮膚用保湿剤。 2 剤が化粧石鹸、透明石鹸、又はクレンジング
クリーム等の洗浄料、コールドクリーム、ハンド
クリーム、バニシングクリーム、フアンデーシヨ
ンクリーム、ホルモンクリームなどのクリーム
類、植物汁液性化粧水、アルカリ性化粧水、アス
トリンジエントローシヨン、ハンドローシヨン、
乳液、フアンデーシヨンローシヨン、クレンジン
グローシヨンなどの化粧水類、粉オシロイ、水オ
シロイ、練オシロイなどのオシロイ類及び口紅か
ら選ばれた皮膚用化粧品の剤形を与えられている
特許請求の範囲第1項記載の皮膚用保湿剤。[Claims] 1. A skin moisturizer containing polysulfate of chondroitin sulfate as an active ingredient. 2. The agent is cosmetic soap, transparent soap, cleansing cream such as cleansing cream, creams such as cold cream, hand cream, vanishing cream, foundation cream, hormone cream, plant juice lotion, alkaline lotion, astringent lotion, etc. enlotsion, hand lotion,
The scope of the patent claims provides a dosage form for skin cosmetics selected from lotions such as emulsions, foundation lotions, and cleansing lotions, cosmetics such as powdered cosmetics, water supplements, and kneaded cosmetics, and lipsticks. The skin moisturizer according to item 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58221708A JPS60112708A (en) | 1983-11-24 | 1983-11-24 | Humectant for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58221708A JPS60112708A (en) | 1983-11-24 | 1983-11-24 | Humectant for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60112708A JPS60112708A (en) | 1985-06-19 |
JPS624362B2 true JPS624362B2 (en) | 1987-01-30 |
Family
ID=16771024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58221708A Granted JPS60112708A (en) | 1983-11-24 | 1983-11-24 | Humectant for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60112708A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11274165B2 (en) | 2017-02-28 | 2022-03-15 | Oji Holdings Corporation | Pentosan polysulfate, pharmaceutical composition, and anticoagulant |
US11278485B2 (en) | 2017-05-31 | 2022-03-22 | Oji Holdings Corporation | Moisturizing topical preparation |
US11286272B2 (en) | 2016-08-31 | 2022-03-29 | Oji Holdings Corporation | Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide |
US11312790B2 (en) | 2016-08-31 | 2022-04-26 | Oji Holdings Corporation | Production method for pentosan polysulfate |
US11344570B2 (en) | 2017-12-20 | 2022-05-31 | Oji Holdings Corporation | Pentosan polysulfate and medicine containing pentosan polysulfate |
US11390693B2 (en) | 2017-09-12 | 2022-07-19 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6456611A (en) * | 1987-08-25 | 1989-03-03 | Hoou Kk | Hair dye composition |
WO1996011693A1 (en) * | 1994-10-12 | 1996-04-25 | Taisho Pharmaceutical Co., Ltd. | Dermatosis remedy |
EP1698641B1 (en) | 2005-03-01 | 2011-09-28 | JNC Corporation | Compound selected from sulfated cellulose and salts thereof and dermatitis therapeutic agent |
JP6726498B2 (en) * | 2016-03-28 | 2020-07-22 | 小林製薬株式会社 | External composition |
US20190269589A1 (en) * | 2018-03-01 | 2019-09-05 | Gojo Industries, Inc. | Alcohol-based hand conditioners for repeated use |
CN108578262B (en) * | 2018-03-30 | 2020-04-21 | 浙江工业大学 | Preparation method of moisturizing lipstick containing alkannin liposome |
JPWO2020138403A1 (en) | 2018-12-27 | 2021-11-11 | ライオン株式会社 | External composition for skin and aerosol |
-
1983
- 1983-11-24 JP JP58221708A patent/JPS60112708A/en active Granted
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11286272B2 (en) | 2016-08-31 | 2022-03-29 | Oji Holdings Corporation | Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide |
US11312790B2 (en) | 2016-08-31 | 2022-04-26 | Oji Holdings Corporation | Production method for pentosan polysulfate |
US11274165B2 (en) | 2017-02-28 | 2022-03-15 | Oji Holdings Corporation | Pentosan polysulfate, pharmaceutical composition, and anticoagulant |
US11278485B2 (en) | 2017-05-31 | 2022-03-22 | Oji Holdings Corporation | Moisturizing topical preparation |
US11390693B2 (en) | 2017-09-12 | 2022-07-19 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
US11344570B2 (en) | 2017-12-20 | 2022-05-31 | Oji Holdings Corporation | Pentosan polysulfate and medicine containing pentosan polysulfate |
Also Published As
Publication number | Publication date |
---|---|
JPS60112708A (en) | 1985-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69400333T2 (en) | Cosmetic and dermatological compositions containing a combination of ceramides and linoleic acid | |
JP3112436B2 (en) | In particular, the use of honey as a keratolytic agent to improve the brightness of the skin facial and treat wrinkles | |
TW457094B (en) | Topical composition for enhancing lipid barrier synthesis | |
JPH06506668A (en) | Use of growth factors in slimming compositions | |
EP0440058B1 (en) | Cosmetic composition | |
JPH0375523B2 (en) | ||
JP4813690B2 (en) | Filaggrin synthesis promoter, stratum corneum moisturizing function improving / enhancing agent and stratum corneum free amino acid content increasing agent | |
JPS624362B2 (en) | ||
JPH07277939A (en) | Skin external preparation | |
JP2010520232A (en) | External preparation composition containing ginseng extract and its use as a skin moisturizing cosmetic | |
JPS62292710A (en) | Skin cosmetic | |
JP2572730B2 (en) | Skin cosmetics | |
JP2003300862A (en) | Use of sapogenin or use of sapogenin-containing plant extract for treatment of hyposeborrheic dry skin | |
US20180353413A9 (en) | Skin compositions containing hydrocortisone | |
JPH01275511A (en) | External drug for skin | |
KR101605324B1 (en) | Cosmetic composition for moisturizing skin which alleviates itchiness and dryness by removing keratin and increasing moisture | |
KR101155807B1 (en) | Cosmetic composition for moisturizing and firming the skin | |
JP5306725B2 (en) | Topical skin preparation | |
JPH10114670A (en) | Composition suitable for external use | |
JPH11139951A (en) | Cosmetic | |
KR101648466B1 (en) | Cosmetic composition for improving skin | |
JPS6351312A (en) | Skin beautifying cosmetic | |
JPH09286709A (en) | Preparation for external use for skin | |
JPH082772B2 (en) | Sebum secretagogue | |
JP2004075635A (en) | Moisturizing agent and external preparation for skin |